Navigation Links
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
Date:9/24/2008

are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

-- our ability to obtain necessary financing;

-- our ability to control our operating expenses;

-- our ability to recruit and enroll patients for the FDG-PET clinical

trial;

-- failure to obtain sufficient data from enrolled patients that can be

used to evaluate VIA-2291, thereby impairing the validity or

statistical significance of our clinical trials;

-- our ability to successfully complete our clinical trials of VIA-2291 on

expected timetables and the outcomes of such clinical trials;

-- complexities in designing and implementing cardiovascular clinical

trials using histological examinations, measurement of biomarkers,

medical imaging and atherosclerotic plaque bioassays;

-- the results of our clinical trials, including without limitation, with

respect to the safety and efficacy of VIA-2291;

-- the outcome of any legal proceedings;

-- our ability to obtain necessary FDA approvals;

-- our ability to successfully commercialize VIA-2291;

-- our ability to obtain and protect our intellectual property related to

our product candidates;

-- our potential for future growth and the development of our product

pipeline;

-- our ability to form and maintain collaborative relationships to develop

and commercialize our product candidates;

-- general economic and business conditions; and

-- the other risks described under Item IA "Risk Factors" in our Annual

Report on Form 10-K for the fiscal year ended December 31, 2007 on file

with the SEC.

All forward-looking statements attributable to us or persons acting
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... Chief Executive Officer, will be presenting at the 26 th ... Palace Hotel in New York . The ... 2:00 PM ET. In addition, Mr. Krakauer and Jorgen ... separate one-on-one meetings during the day. An ...
(Date:11/21/2014)... , Nov. 20, 2014  The acceptance ... the 2014 AAGL Global Congress demonstrates continued interest ... designed to provide bowel control. One of the abstracts, ... Professor and Division Chief of Urogynecology and Reconstructive ... won an Award for Best Written Abstract on ...
(Date:11/21/2014)... , Nov. 20, 2014   Coqui RadioPharmaceuticals Corp. ... first U.S. commercial producer of Molybdenum-99 (Mo-99), is proud ... INVAP to design its Medical Isotope Production ... Mo-99 is the parent isotope of Technetium-99, which is ... In 2012, Congress passed legislation making it a national ...
Breaking Medicine Technology:LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2
(Date:11/22/2014)... 2014 "My friend went in for ... the machine," said an inventor from Cambria Heights, N.Y. ... back a second time because the first results were ... developed the patent-pending MAMO EASY to offer a more ... saves the patient from the pain normally involved with ...
(Date:11/22/2014)... 2014 The topic of B&D Rockeries’ ... retaining walls. The article states that, “While they give off ... steps that go into creating this powerful look.” , One ... wall is choosing which kind of block matches your home ... Rockeries says, “The two main options are concrete and stone ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Recently, UWDress.com ... wedding guest dresses . In addition, the company ... products. , As a leading online supplier of ... of beautiful outfits. The unusual best wedding guest gowns ... Besides the amazing designs, this new selection is famous ...
(Date:11/22/2014)... JOSE, Calif. (PRWEB) November 22, 2014 ... security applications was announced today which safely detects ... using high frequency radio waves. Developed by RHT ... images and hosts broad applications in other areas ... addition to security. , Using high frequency radio ...
(Date:11/22/2014)... OH (PRWEB) November 22, 2014 A Xarelto ... York woman who is seeking $10 million in damages from ... thinner . According to the lawsuit, the woman began using ... The woman alleges in her lawsuit she suffered life-threatening bleeding ... permanent personal injuries, pain, suffering and emotional distress. The lawsuit ...
Breaking Medicine News(10 mins):Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:RHT SpectraSafe announces a Radical New Airport Security Technology that Is More Effective, Less Invasive 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 4
... Decreased muscle strength is associated with difficulty in ... kneeling (SCK) in older adults, according to an ... Physical Therapy (PTJ), the scientific journal ... researchers found that adults with SCK difficulty had ...
... They differ from each other in many ways, and they ... HIV to resist a host of weapons fired at ... emerging. One potential weapon is a small-molecule ... by attacking them through some feature common to an entire ...
... ... a Soho Seminar event that will help you transform the way employees engage inside and ... ... at the Soho Seminars event “Aligning the Corporate and Personal Brand,” hosted by Loyola ...
... effect on heart from androgen deprivation, official says ... with prostate cancer and the physicians who treat ... (ADT) commonly used against the malignancy might increase ... , "There is a substantial amount of data ...
... , PHILADELPHIA , ... GlaxoSmithKline plc will announce its full year financial results for the ... the announcement will be released to the London Stock Exchange at ... www.gsk.com . , Following the announcement, Andrew Witty , ...
... , , Rare, but serious, liver disorder ... 1 The U.S. Food and Drug Administration today announced ... has been reported in some HIV patients taking Videx/Videx EC ... is an antiretroviral medicine first approved by the FDA in ...
Cached Medicine News:Health News:Decreased muscle strength predicts functional impairments in older adults 2Health News:Decreased muscle strength predicts functional impairments in older adults 3Health News:Researchers find 'broad spectrum' antiviral that fights multitude of viruses 2Health News:Researchers find 'broad spectrum' antiviral that fights multitude of viruses 3Health News:7Summits to Present at Soho Seminars 'Alignment of Personal and Corporate Brands' 2Health News:Experts Issue Warning on Prostate Hormone Therapy 2Health News:Experts Issue Warning on Prostate Hormone Therapy 3Health News:GSK 2009 Financial Results Announcement and Teleconference Details 2Health News:FDA Announces Safety Risk Associated with HIV Drug 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: